Search Results

You are looking at 191 - 200 of 383 items for :

  • "Neutropenia" x
  • Refine by Access: All x
Clear All
Full access

Idelalisib and Rituximab in 17p Deletion–Positive Splenic Marginal Zone Lymphoma

Aby Z. Philip

catheter improved significantly and albumin infusions were discontinued. She tolerated idelalisib well without any significant issues, except for one episode of mild neutropenia that resolved with temporary discontinuation of the drug. Five months into

Full access

Updates in the Management of Small Cell Lung Cancer

Presented by: Apar Kishor Ganti

.3–11.8 months). 14 The main toxicity was hematologic, with 5% of patients experiencing neutropenia. A review of various cytotoxic agents studied worldwide for relapsed SCLC revealed that combination carboplatin, ifosfamide, and etoposide (CIE) yielded the

Full access

Maneuvering the Complex Web of Treatment Options for Relapsed/Refractory Multiple Myeloma

Presented by: Natalie S. Callander

of 4.2 months, and a median overall survival of 11.6 months. Grade 3/4 hematologic adverse events were common (neutropenia [79%], thrombocytopenia [76%], and anemia [71%]), but were clinically manageable. Nonhematologic adverse events were infrequent

Full access

Targeted Therapy for Metastatic Non–Small Cell Lung Cancer

Presented by: Gregory J. Riely

compared with docetaxel,” he said, especially with less neutropenia and alopecia. The NCCN Guidelines recommend sotorasib or adagrasib as second-line therapy options in patients with KRAS G12C mutation–positive metastatic NSCLC. 4 “So, in the second

Full access

Vaccinations for Patients With Cancer and Cancer Survivors

Presented by: Maria Alma Rodriguez

“While under active treatment, patients with cancer are vulnerable to infection, as chemotherapy, radiation therapy, and immune-altering therapies can lead to neutropenia, lymphopenia, and altered immune competence,” commented Maria Alma Rodriguez

Full access

NCCN Guidelines Update: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Presented by: Deborah M. Stephens

leading to treatment discontinuation with zanubrutinib. One notable side effect of zanubrutinib was a tendency to cause more neutropenia, although this did not correlate to neutropenic fever or higher rates of grade 3 infections. “The findings of these 2

Full access

Advances in the Management of Classical Hodgkin Lymphoma

Presented by: Ryan C. Lynch

=.0005). 10 Despite these “promising” results, according to Dr. Lynch, longer-term follow-up data are needed before this regimen may be considered for integration into the NCCN Guidelines. “Notably, there is more neutropenia with N-AVD,” he added

Full access

New Settings for Immune Checkpoint Inhibitors in Urothelial Cancer

Presented by: Arlene O. Siefker-Radtke

properties as well, according to Dr. Siefker-Radtke. She also stated that neutropenia and lymphopenia are frequently reported with agents such as gemcitabine, which could impact the ability to induce an immune response. A phase II study showed evidence of

Full access

Effect of Hepatitis C Virus Infection in Patients With Cancer: Addressing a Neglected Population

Harrys A. Torres, Parag Mahale, Boris Blechacz, Ethan Miller, Ahmed Kaseb, H. Franklin Herlong, Nathan Fowler, Ying Jiang, Issam I. Raad, and Dimitrios P. Kontoyiannis

baseline hematologic abnormalities (ie, neutropenia) can be exacerbated by interferon (IFN) alfa and ribavirin-containing HCV therapy. 10 Other reasons for excluding these patients is the potential for HCV to affect the toxicity and/or efficacy of the

Full access

Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology

Daniel A. Pollyea, Jessica K. Altman, Rita Assi, Dale Bixby, Amir T. Fathi, James M. Foran, Ivana Gojo, Aric C. Hall, Brian A. Jonas, Ashwin Kishtagari, Jeffrey Lancet, Lori Maness, James Mangan, Gabriel Mannis, Guido Marcucci, Alice Mims, Kelsey Moriarty, Moaath Mustafa Ali, Jadee Neff, Reza Nejati, Rebecca Olin, Mary-Elizabeth Percival, Alexander Perl, Amanda Przespolewski, Dinesh Rao, Farhad Ravandi, Rory Shallis, Paul J. Shami, Eytan Stein, Richard M. Stone, Kendra Sweet, Swapna Thota, Geoffrey Uy, Pankit Vachhani, Carly J. Cassara, Deborah A. Freedman-Cass, and Katie Stehman

neutropenia, myelosuppression was generally modest and reversible, potentially reflecting the minimal expression of IL3R on normal myeloid progenitors. Many patients experienced transaminitis without hyperbilirubinemia, with onset typically 5 to 10 days